Secretome Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $30M

  • Investors
  • 8

Secretome Therapeutics General Information

Description

Developer of cell-based therapy designed for people who experience a heart attack and patients with heart failure. The company's therapy is developed from neonatal cardiac progenitor cells derived from tissue discarded during lifesaving heart surgery in babies with congenital heart conditions, enabling medical practitioners to treat patients suffering from heart failure.

Contact Information

Website
www.secretometherapeutics.com
Formerly Known As
NeoProgen
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 323 West Camden Street
  • Suite 600
  • Baltimore, MD 21201
  • United States
+1 (410)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 323 West Camden Street
  • Suite 600
  • Baltimore, MD 21201
  • United States
+1 (410)

Secretome Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Secretome Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 27-May-2026 $30M Completed Clinical Trials - Phase 1
4. Grant 24-Mar-2026 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series A) 25-Nov-2024 Completed Clinical Trials - Phase 1
2. Later Stage VC 02-Feb-2023 $6.85M $8.35M Completed Pre-Clinical Trials
1. Seed Round 16-Oct-2019 $1.5M $1.5M Completed Pre-Clinical Trials
To view Secretome Therapeutics’s complete valuation and funding history, request access »

Secretome Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
Series A-2
Series A-1
Seed-1 5,379,767 $0.000100 $0.58 $0.58 1x $0.58 3.28%
Seed 4,324,310 $0.000100 $0.81 $0.81 1x $0.81 2.64%
To view Secretome Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Secretome Therapeutics Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • 5

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Secretome Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026192962-A2 Methods of treating dystrophinopathies Pending 10-Mar-2025
WO-2026192962-A3 Methods of treating dystrophinopathies Pending 10-Mar-2025
WO-2026192965-A1 Methods of treating heart failure with preserved ejection fraction Pending 10-Mar-2025
WO-2026096307-A1 Methods of treating amyotrophic lateral sclerosis Pending 28-Oct-2024
AU-2020383622-A1 Immortalized cardiac stem cells for cardiac repair Pending 15-Nov-2019 A61K35/34
To view Secretome Therapeutics’s complete patent history, request access »

Secretome Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Secretome Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
RA Capital Management Asset Manager Minority
Parent Project Muscular Dystrophy Not-For-Profit Venture Capital
Huffines Enterprises Science & Technology Investments Venture Capital Minority
Angel (individual) Minority
TEDCO Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Secretome Therapeutics FAQs

  • When was Secretome Therapeutics founded?

    Secretome Therapeutics was founded in 2018.

  • Where is Secretome Therapeutics headquartered?

    Secretome Therapeutics is headquartered in Baltimore, MD.

  • What is the size of Secretome Therapeutics?

    Secretome Therapeutics has 20 total employees.

  • What industry is Secretome Therapeutics in?

    Secretome Therapeutics’s primary industry is Drug Discovery.

  • Is Secretome Therapeutics a private or public company?

    Secretome Therapeutics is a Private company.

  • What is the current valuation of Secretome Therapeutics?

    The current valuation of Secretome Therapeutics is .

  • What is Secretome Therapeutics’s current revenue?

    The current revenue for Secretome Therapeutics is .

  • How much funding has Secretome Therapeutics raised over time?

    Secretome Therapeutics has raised $62.4M.

  • Who are Secretome Therapeutics’s investors?

    RA Capital Management, Parent Project Muscular Dystrophy, Huffines Enterprises Science & Technology Investments, , and TEDCO are 5 of 8 investors who have invested in Secretome Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process